Tag
This review synthesizes recent evidence on the massive scale of CKM medication eligibility in the US, the synergistic effects of pharmacotherapy with lifestyle, and emerging neuropsychiatric benefits of GLP-1 receptor agonists.
This review synthesizes population-level data on the eligibility for GLP-1RAs, SGLT2is, and nsMRAs, highlighting that over 60% of US adults meet indications for these transformative therapies.
This review synthesizes evidence comparing SGLT2 inhibitors and GLP-1 receptor agonists, highlighting a significant reduction in chronic kidney disease and acute kidney injury risks associated with SGLT2i initiation.
In a 241,981-patient emulated trial using modern causal methods, sustained GLP‑1RA use yielded the lowest 2.5‑year MACE risk, followed by SGLT2is, sulfonylureas, and DPP4is; the GLP‑1RA advantage over SGLT2is was greatest in older adults an
